Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia
Portfolio Pulse from Benzinga Newsdesk
Reviva Pharmaceuticals (NASDAQ:RVPH) announced that over 80% of patients have been enrolled in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for the treatment of schizophrenia. Enrollment is ongoing at multiple sites in the United States, Europe, and Asia.
June 22, 2023 | 10:03 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reviva Pharmaceuticals has enrolled over 80% of patients in the Phase 3 RECOVER study for brilaroxazine, a potential schizophrenia treatment.
The announcement of 80% enrollment in the Phase 3 RECOVER study indicates progress in the development of brilaroxazine for schizophrenia treatment. This positive news may lead to increased investor confidence and a potential short-term increase in RVPH's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100